Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Background: To date, there is no accepted clinical diagnostic test for Parkinson disease (PD) that is based on biochemical analysis of blood or CSF. The discovery of mutations in the SNCA gene encoding α-synuclein in familial parkinsonism and the accumulation of α-synuclein in the PD brain suggested a critical role for this protein in PD etiology.
Methods: We investigated total and α-synuclein oligomers levels in CSF from patients clinically diagnosed with PD, progressive supranuclear palsy (PSP), or Alzheimer disease (AD), and age-matched controls, using ELISA developed in our laboratory.
Results: The levels of α-synuclein oligomers and oligomers/total-α-synuclein ratio in CSF were higher in the PD group (n = 32; p < 0.0001, Mann-Whitney U test) compared to the control group (n = 28). The area under the receiver operating characteristic curve (AUC) indicated a sensitivity of 75.0% and a specificity of 87.5%, with an AUC of 0.859 for increased CSF α-synuclein oligomers in clinically diagnosed PD cases. However, when the CSF oligomers/total-α-synuclein ratio was analyzed, it provided an even greater sensitivity of 89.3% and specificity of 90.6%, with an AUC of 0.948. In another cross-sectional pilot study, we confirmed that the levels of CSF α-synuclein oligomers were higher in patients with PD (n = 25) compared to patients with PSP (n = 18; p < 0.05) or AD (n = 35; p < 0.001) or control subjects (n = 43; p < 0.05).
Conclusion: Our results demonstrate that levels of α-synuclein oligomers in CSF and the oligomers/total-α-synuclein ratio can be useful biomarkers for diagnosis and early detection of PD.
Footnotes
-
Study funding: The laboratory of O.M.E. is supported by the Michael J. Fox Foundation for Parkinson's Research.
-
- AD
- Alzheimer disease
- AUC
- area under the receiver operating characteristic curve
- DC
- disease control
- DLB
- dementia with Lewy bodies
- DSM-IV
- Diagnostic and Statistical Manual of Mental Disorders, 4th edition
- HRP
- horseradish peroxidase
- LB
- Lewy body
- mAb
- monoclonal antibody
- NC
- normal control
- PBS
- phosphate-buffered saline
- PBST
- PBS containing 0.05% Tween 20
- PD
- Parkinson disease
- PSP
- progressive supranuclear palsy
- RLU
- relative luminescence units
- ROC
- receiver operating characteristic.
Editorial, page 1760
Supplemental data at www.neurology.org
- Received September 1, 2009.
- Accepted May 25, 2010.
- Copyright © 2010 by AAN Enterprises, Inc.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Disputes & Debates: Rapid online correspondence
- Detection of elevated levels of -synuclein oligomers in CSF from patients with Parkinson disease
- Kim A. Bruggink, Department of Neurology, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, The NetherlandsK.Bruggink@neuro.umcn.nl
- H. Bea Kuiperij, Frida Ekholm-Pettersson (Uppsala University, Sweden), Marcel M. Verbeek Radboud University Nijmegen Medical Centre, The Netherlands
Submitted February 17, 2011 - Reply from the authors
- Omar M. A. El-Agnaf, United Arab Emirates University, United Arab Emirates University, 17666 Al-Ain, United Arab Emirateso.elagnaf@uaeu.ac.ae
- Takahiko Tokuda
Submitted February 17, 2011
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.

